Last reviewed · How we verify
NCT06781255
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
Phase 1 trial testing Kamuvudine-9 in Diabetic Macular Edema in 1 participant. Terminated before completion.
25 February 2026
Quick facts
| Lead sponsor | Michelle Abou-Jaoude |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1 |
| Start date | 13 March 2025 |
| Primary completion | 25 February 2026 |
| Estimated completion | 25 February 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Kamuvudine-9 — full drug profile →
Conditions studied
- Diabetic Macular Edema — all drugs for Diabetic Macular Edema →
Sponsor
Michelle Abou-Jaoude — full company profile →
Who can join
Adults 18 to 89, any sex, with Diabetic Macular Edema. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A non-randomized study evaluating the safety of an orally administered inflammasome inhibitor, K9, for the treatment of diabetic macular edema (DME).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Association of nucleoside reverse transcriptase inhibitor use with reduced risk of Alzheimer's disease risk.
Magagnoli J, Ambati M, Cummings TH, Nguyen J, et al · · 2025 · cited 13× · PMID 40342195 · DOI 10.1002/alz.70180
Verify or expand the search:
- PubMed search for NCT06781255
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Kamuvudine-9
Trials testing the same drug.
- NCT06467435 — Evaluation of K9 in Subjects With Thyroid Eye Disease (TED) · Phase 1 · terminated
Other recruiting trials for Diabetic Macular Edema
Currently open trials in the same condition.
- NCT07425522 — A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With D · Phase 1 · recruiting
- NCT06984822 — Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant · NA · recruiting
- NCT07038967 — Non-Center Involving Diabetic Macular Edema Progression in Early Postoperative Period After Phacoemulsification · recruiting
- NCT06680817 — A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) · recruiting
- NCT06549023 — Single Session vs Multiple-Session Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy · NA · recruiting
Other Michelle Abou-Jaoude trials
Trials by the same sponsor.
- NCT05699759 — Safety and Effect of Intravitreal Injection of a Derivative of Nucleoside Reverse Transcriptase Inhibitor in Subjects wi · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06781255 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Michelle Abou-Jaoude
- Last refreshed: 6 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06781255.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing